background

See beyond appearances

1 in 3 cancers is a skin cancer

Skin cancer is the most commonly occurring cancer in humans, with an incidence that has steadily increased worldwide. The prognosis of advanced melanoma is poor, and carcinomas are associated with high morbidity.        

60% biopsies result in benign diagnoses

Although dermoscopy is a useful tool for clinical examination, the sensitivity of dermoscopic monitoring is limited by melanomas that may arise in normal skin or in clinically benign nevi that were not initially photographed (link).

20% skin cancers missed at early stage

Dermoscopy improves the diagnostic accuracy for melanoma but only for experienced examiners. Dermoscopy by untrained or less experienced examiners is no better than clinical inspection without dermoscopy (link).

Discover deepLive™

DAMAE Medical develops deepLive™ medical device, the new best-in-class imaging system pairing penetration and cellular resolution in 3D. deepLive™ is adapted to the imaging of multiple skin conditions, promoting efficient, reassuring and non-invasive patient management.

image

Based on LC-OCT™ innovative technology

deepLive™ integrates LC-OCT (Line-field Confocal Optical Coherence Tomography) technology which provides a unique 3D imaging modality, allowing the user to   switch from a histology-like vertical mode to a confocal-like horizontal mode,    and to record a 3D stack of tissue volumes in situ. 

  • Image


Navigations in LC-OCT™ 3D stacks

image

LC-OCT™ imaging of the back of a hand

image

LC-OCT™ imaging of a fingerprint

  • Image


Quantitative skin analyses
adapted to your studies

  • Image

    Skin Surface 3D segmentation

  • Image

    Dermo-Epidermal Junction 3D segmentation

  • Image

    Keratinocytes distribution

  • Image

    Keratinocytes density with depth

  • Image

    Collagen fibers segmentation


Our company

2014

> Company established by Anaïs BARUT (CEO), David SIRET (CTO), Arnaud DUBOIS (CSO) who filed the patent protecting LC-OCT's technology 
> Proof of concept of LC-OCT vertical imaging

2015

> First LC-OCT images performed on fresh biopsies of suspected skin cancer
> Validation of the potential of LC-OCT vertical imaging for the 2 main types of skin cancer: carcinoma and melanoma

2016

> First clinical demonstrator installed at the Saint-Etienne University Hospital
> Winner of the Digital Innovation Competition organized by Bpifrance
> Signature of the exclusive license agreement for LC-OCT technology

2017

> Closing of a €2 million investment round with Kurma Partners, Idinvest Partners, News Invest, Paris-Saclay Seed Fund co-managed by Partech Ventures, and private investors
> Obtaining ISO 13485 certificate
> First proof of concept of LC-OCT 3D

2018

> Winner of the World Competition of Innovation organized by Bpifrance
> Miniaturized LC-OCT 2D in a handheld probe
> Obtaining CE-marking LC-OCT 2D
> Installation of LC-OCT 2D devices in hospitals
> First scientific publication: A. Dubois and al., “LC-OCT for high-resolution noninvasive imaging of skin tumors”, JBO 23, 106007

2019

> Miniaturized LC-OCT 3D in a handheld probe  > Obtaining CE-marking LC-OCT 3D
> Manufacturing of 10 LC-OCT 3D devices
> Launch of clinical validation of LC-OCT 3D

2020

> Integration of the live dermoscopic camera inside the handheld probe 
> Obtaining the CE mark for deepLive™
> First descriptive clinical publications
> Commercial launch of deepLive™ in Europe

image

Pr. Arnaud DUBOIS presents LC-OCT technology

image

3 key numbers in the development of DAMAE Medical

Latest News

Image
October 2020
Latest publication on LC-OCT technology in Skin Research & Technology
Read More
Image
July 2020
DAMAE Medical winner of the Health Data Hub call for projects 
Read More
Image
September 2019
DAMAE Medical receives €2.4 million from European Union’s Horizon 2020 
Read More


Contact us

DAMAE Medical
14 rue Sthrau
75013 Paris
France

M: info@damae-medical.com
P: +33 1 44 49 04 10

If you are looking for a position or an internship, send your CV to job@damae-medical.com
We will get back to you as soon as possible.